Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer

• Published in: Clinical chemistry and laboratory medicine Vol. 45; no. 7; p. 822
• Main Authors: Ruzzo, Annamaria, Canestrari, Emanuele, Maltese, Paolo, Pizzagalli, Francesca, Graziano, Francesco, Santini, Daniele, Catalano, Vincenzo, Ficarelli, Rita, Mari, Davide, Bisonni, Renato, Giordani, Paolo, Giustini, Lucio, Lippe, Paolo, Silva, Rosarita, Mattioli, Rodolfo, Torresi, Umberto, Latini, Luciano, Magnani, Mauro
• Format: Journal Article
• Language: English
• Published: Germany 01-07-2007
• Subjects: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; DNA Repair - genetics; Female; Genetic Predisposition to Disease; Genotype; Humans; Italy; Male; Middle Aged; Polymorphism, Genetic; Risk Factors; Stomach Neoplasms - genetics; Stomach Neoplasms - metabolism; Xenobiotics - metabolism; Italy
• ISSN: 1434-6621
• DOI: 10.1515/CCLM.2007.143

Gastric cancer is the second highest cause of cancer mortality in the world, despite declining rates of incidence in many industrialized countries. We carried out a case-control study to evaluate whether polymorphisms of DNA repair and glutathione S-transferase (GST) genes modulate the risk of developing diffuse gastric cancer.
ERCC1 118 T/C, XRCC1 399 G/A, XPD 312 G/A, XPD 751 A/C, XRCC3 241 C/T, MS 919 A/G, GSTP1 105 A/G, GSTM1-null/positive and GSTT1-null/positive genotypes were obtained for a series of 126 Helicobacter pylori-negative diffuse gastric cancer patients and 144 Helicobacter pylori-negative controls sampled from the population of Marche, an area with high gastric cancer risk in central Italy.
GSTP1 105 A/G and GSTP1 105 G/G genotypes were identified as protective factors, with odds ratio (OR) of 0.4 (95% CI 0.17-0.81, p=0.01) and OR=0.58 (95% CI 0.33-1, p=0.05), respectively. GSTT1-null genotype was identified as a protective factor, with OR=0.48 (95% CI 0.22-0.99, p=0.04). There was no significant difference between cases and controls for XPD 751 A/C, ERCC1 118 T/C, XRCC3 241 C/T, XRCC1 399 G/A, XPD 312 G/A, GSTM1-null/positive and MS 919 A/G polymorphisms.
This study suggests that GSTP1 105A/G and GSTT1-null/positive genotypes might be associated with a reduced risk for sporadic diffuse gastric cancer. Clin Chem Lab Med 2007;45:822-8.